The Columbia Biomedical Technology Accelerator | Columbia BiomedX (formally Columbia-Coulter Translational Research Partnership) aims to catalyze the advancement of biomedical innovations by providing funding, education, resources and mentorship to interdisciplinary teams of clinicians, engineers, scientists and students working to develop solutions to clinical unmet needs, with the ultimate goal of bringing innovative research out of the lab to benefit society. Project support is expected to serve as a bridge to commercial investment, with awards granted to perform specific tasks needed to validate a commercial hypothesis (vs. a scientific hypothesis). PRE-PROPOSALS due by DEC 1.
Visit www.columbiabiomedx.com for more details.
The most recently funded projects span a broad range of topics and scientific areas, including development of a reparative patch for herniated discs, a software-based analysis process to generate a velocity map of atrial fibrillation, an improved cell production system for cancer immunotherapy, a storage and transportation device for fresh osteochondral allografts, novel methods for allograft bending and engineering allografts for knee repair, and software for analyzing core infarct volume in strokes.
Projects are selected for their commercialization potential, and ultimately their potential to improve human health. “For those faculty who are so inclined, the Coulter Program is an incredible asset to take the step toward translating technology to have an impact on society,” said Professor Andrew Laine, Chair of the Department of Biomedical Engineering and Principal Investigator for the Columbia-Coulter program.
Once selected, teams have access to expertise from leaders in business, medicine, and engineering in the form of the Columbia-Coulter Oversight Committee and other business advisors. “The gem, the gold, or the platinum in the program is the wisdom of the Oversight Committee,” said Laine. “The savvy of the people who serve on the committee is the real resource that the program provides, and this has added value to the entire academic program.”
Visit www.columbiabiomedx.com for more details.
The most recently funded projects span a broad range of topics and scientific areas, including development of a reparative patch for herniated discs, a software-based analysis process to generate a velocity map of atrial fibrillation, an improved cell production system for cancer immunotherapy, a storage and transportation device for fresh osteochondral allografts, novel methods for allograft bending and engineering allografts for knee repair, and software for analyzing core infarct volume in strokes.
Projects are selected for their commercialization potential, and ultimately their potential to improve human health. “For those faculty who are so inclined, the Coulter Program is an incredible asset to take the step toward translating technology to have an impact on society,” said Professor Andrew Laine, Chair of the Department of Biomedical Engineering and Principal Investigator for the Columbia-Coulter program.
Once selected, teams have access to expertise from leaders in business, medicine, and engineering in the form of the Columbia-Coulter Oversight Committee and other business advisors. “The gem, the gold, or the platinum in the program is the wisdom of the Oversight Committee,” said Laine. “The savvy of the people who serve on the committee is the real resource that the program provides, and this has added value to the entire academic program.”